- Phare
- Validé par KD/KO
Anticorps Polyclonal de lapin anti-SMAD7
SMAD7 Polyclonal Antibody for IHC, WB, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain, souris et plus (1)
Applications
WB, IP, IHC, IF, CoIP, ELISA
Conjugaison
Non conjugué
N° de cat : 25840-1-AP
Synonymes
Galerie de données de validation
Applications testées
Résultats positifs en WB | cellules HEK-293, cellules HepG2, cellules NIH/3T3, cellules SH-SY5Y, cellules SW480 |
Résultats positifs en IHC | tissu hépatique de souris, il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. |
Dilution recommandée
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:500-1:3000 |
Immunohistochimie (IHC) | IHC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, check data in validation data gallery |
Applications publiées
KD/KO | See 6 publications below |
WB | See 86 publications below |
IHC | See 6 publications below |
IF | See 6 publications below |
IP | See 2 publications below |
CoIP | See 1 publications below |
Informations sur le produit
25840-1-AP cible SMAD7 dans les applications de WB, IP, IHC, IF, CoIP, ELISA et montre une réactivité avec des échantillons Humain, souris
Réactivité | Humain, souris |
Réactivité citée | rat, Humain, souris |
Hôte / Isotype | Lapin / IgG |
Clonalité | Polyclonal |
Type | Anticorps |
Immunogène | SMAD7 Protéine recombinante Ag13688 |
Nom complet | SMAD family member 7 |
Masse moléculaire calculée | 426 aa, 46 kDa |
Poids moléculaire observé | 45-55 kDa |
Numéro d’acquisition GenBank | BC074819 |
Symbole du gène | SMAD7 |
Identification du gène (NCBI) | 4092 |
Conjugaison | Non conjugué |
Forme | Liquide |
Méthode de purification | Purification par affinité contre l'antigène |
Tampon de stockage | PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3 |
Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
SMAD7, also named as Mothers against decapentaplegic homolog 7, is a 426 amino acid protein, which belongs to the dwarfin/SMAD family. SMAD7 Interaction with NEDD4L or RNF111 induces translocation from the nucleus to the cytoplasm (PubMed:16601693). TGF-beta stimulates its translocation from the nucleus to the cytoplasm. PDPK1 inhibits its translocation from the nucleus to the cytoplasm in response to TGF-beta (PubMed:17327236). SMAD7 as antagonist of signaling by TGF-beta type 1 receptor superfamily members has been shown to inhibit TGF-beta and activin signaling by associating with their receptors thus preventing SMAD2 access. SMAD7 functions as an adapter to recruit SMURF2 to the TGF-beta receptor complex and also acts by recruiting the PPP1R15A-PP1 complex to TGFBR1, which promotes its dephosphorylation. SMAD7 positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.
Protocole
Product Specific Protocols | |
---|---|
WB protocol for SMAD7 antibody 25840-1-AP | Download protocol |
IHC protocol for SMAD7 antibody 25840-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Brain Behav Immun MicroRNA-181c promotes Th17 cell differentiation and mediates experimental autoimmune encephalomyelitis. | ||
Nat Commun K235 acetylation couples with PSPC1 to regulate the m6A demethylation activity of ALKBH5 and tumorigenesis | ||
Cell Death Differ REGγ ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radio-therapeutic response by regulating the Smad7-TGF-β pathway. | ||
Hypertension Novel Role for the Immunoproteasome Subunit PSMB10 in Angiotensin II-Induced Atrial Fibrillation in Mice. | ||
Theranostics Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition. |